Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLL4-Fc is a recombinant fusion protein consisting of the extracellular domain of the Notch ligand Delta-like 4 (DLL4) fused to the Fc region of a human immunoglobulin (typically IgG1). It functions as a modulator of the Notch signaling pathway, which is critical for cell fate decisions, hematopoiesis, and angiogenesis. When immobilized on a solid surface, DLL4-Fc acts as a Notch agonist, mimicking the presentation of the ligand to Notch receptors on hematopoietic stem and progenitor cells (HSPCs). This interaction triggers T-cell lineage commitment and is the basis for ex vivo T-cell precursor (PreT) generation platforms, such as the one developed by Smart Immune, which aim to accelerate immune reconstitution following allogeneic hematopoietic cell transplantation. In its soluble form, DLL4-Fc can act as a Notch antagonist or decoy receptor, blocking endogenous DLL4-Notch interactions. This inhibitory property has been explored preclinically for its potential to suppress tumor angiogenesis and metastasis, particularly in models of small cell lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DLL4-Fc.